Informations générales (source: ClinicalTrials.gov)
Establishment of Squamous Cell Organoids of the Head and Neck to Assess Their Response to Innovative Therapies (ORGAVADS)
Observational
Centre Francois Baclesse (Voir sur ClinicalTrials)
juillet 2020
février 2031
29 juin 2024
The emergence of tumor organoid cultures in recent years has made it possible to widen
the repertoire of available preclinical tumor models and to bridge the gap between cell
lines and tumors of xenografted patients in mice (PDXs).These organoids have the
advantages of being able to be amplified fairly quickly after resection of the tumor, of
having unlimited proliferation potential, a high rate of establishment success, and the
possibility of being transfected and cryopreserved. These characteristics therefore allow
them to summarize the clinical spectra of cancers, but also to be models for studying
tumor progression as has been done with organoids for colorectal cancer. They are also
very close morphologically and genetically to the tumor from which they derive.Finally,
clinical trials are underway to determine whether the organoids of mammary, pulmonary and
colorectal cancers can predict the response to patients' treatments and guide the
therapeutic decision.It would therefore be possible to test multiple treatments on
different samples. This would allow screening of a panel of treatments on a given tumor
type but also to test a treatment ex vivo before administering it to the patient in vivo.
This prospect is very interesting in particular in the tumors of the VADS where more than
two thirds of the operated patients will benefit from a complementary treatment by
radiotherapy and / or chemotherapy whose consequences can be important. Despite this
adjuvant management, up to 30% of patients will relapse, highlighting a variable tumor
chemosensitivity. This screening could make it possible to refine the choice of
treatments adapted to each patient and thus limit the undesirable effects.The feasibility
of establishing head and neck squamous cell organoid lines seems encouraging, with
organoids derived from squamous cell carcinoma of the oral cavity and oropharynx having
been recently established.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre François Baclesse - 14076 - Caen - France | Vianney BASTIT, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU de Caen - Caen - France | Emmanuel BABIN, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient over 18 years of age;
- Patient with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or
larynx, classified T3Nx or T4Nx or T2N +, not previously treated;
- Patient to be treated by surgery;
- Patient affiliated to a social security scheme;
- No opposition to participate in the study
- Patient over 18 years of age;
- Patient with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or
larynx, classified T3Nx or T4Nx or T2N +, not previously treated;
- Patient to be treated by surgery;
- Patient affiliated to a social security scheme;
- No opposition to participate in the study
- Pregnant woman ;
- Persons deprived of their liberty or under guardianship (including curatorship);
- History of malignant pathology preceding inclusion (apart from basal cell carcinomas
of the skin and carcinomas in situ of the cervix treated surgically) or concomitant
at inclusion (synchronous tumor)